CD56negCD16+ NK cells are activated mature NK cells with impaired effector function during HIV-1 infection

Retrovirology

Volumn 10, Issue 1, 2013, Pages

  Milush, Jeffrey M ^a   López Vergès, Sandra ^a,d   York, Vanessa A ^a   Deeks, Steven G ^b   Martin, Jeffrey N ^a   Hecht, Frederick M ^b   Lanier, Lewis L ^a   Nixon, Douglas F ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d GORGAS MEMORIAL INSTITUTE FOR HEALTH STUDIES   (Panama)

Author keywords

CD56neg NK cells; CD7; HIV pathogenesis; HIV 1; Human immunodeficiency virus; Natural killer cells; NK cells

Indexed keywords

CD14 ANTIGEN; CD16 ANTIGEN; CD19 ANTIGEN; CD56 ANTIGEN; CD7 ANTIGEN; FAS ANTIGEN; GAMMA INTERFERON; GRANZYME B; HLA DR ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; LECTIN; LECTIN RECEPTOR; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL RECEPTOR NKG2C; PERFORIN; UNCLASSIFIED DRUG; FC RECEPTOR; FCGR3B PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; GRANZYME; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NCAM1 PROTEIN, HUMAN;

ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE RELEASE; EFFECTOR CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION; NATURAL KILLER CELL; PHENOTYPE; PROTEIN EXPRESSION; T LYMPHOCYTE SUBPOPULATION; VIRUS LOAD; BIOSYNTHESIS; CHEMISTRY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; NORMAL HUMAN; SECRETION (PROCESS);

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIGENS, CD56; ANTIGENS, CD7; GPI-LINKED PROTEINS; GRANZYMES; HEALTHY VOLUNTEERS; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; PERFORIN; RECEPTORS, IGG;

EID: 84890398023     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-10-158     Document Type: Article

References (45)

1. Caligiuri MA. Human natural killer cells. Blood 2008, 112:461-469. 10.1182/blood-2007-09-077438, 2481557, 18650461.
2. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008, 9:495-502. 10.1038/ni1581, 2669298, 18425106.
3. Moretta A, Bottino C, Mingari MC, Biassoni R, Moretta L. What is a natural killer cell?. Nat Immunol 2002, 3:6-8. 10.1038/ni0102-6, 11753399.
4. Walzer T, Blery M, Chaix J, Fuseri N, Chasson L, Robbins SH, Jaeger S, Andre P, Gauthier L, Daniel L, et al. Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc Natl Acad Sci USA 2007, 104:3384-3389. 10.1073/pnas.0609692104, 1805551, 17360655.
5. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986, 136:4480-4486.
6. Mansour I, Doinel C, Rouger P. CD16+ NK cells decrease in all stages of HIV infection through a selective depletion of the CD16+CD8+CD3- subset. AIDS Res Hum Retroviruses 1990, 6:1451-1457. 10.1089/aid.1990.6.1451, 2150319.
7. Voiculescu C, Avramescu C, Balasoiu M, Turculeanu A, Radu E. Changes of blood CD16/CD56 (NK) and HLA-DR/CD3-positive lymphocyte amounts in HIV-infected children, as related to clinical progression and p24-antigen/p24-antibody presence. FEMS Immunol Med Microbiol 1994, 9:217-221.
8. Hu PF, Hultin LE, Hultin P, Hausner MA, Hirji K, Jewett A, Bonavida B, Detels R, Giorgi JV. Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16 + CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity. J Acquir Immune Defic Syndr Hum Retroviro 1995, 10:331-340.
9. Alter G, Teigen N, Davis BT, Addo MM, Suscovich TJ, Waring MT, Streeck H, Johnston MN, Staller KD, Zaman MT, et al. Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood 2005, 106:3366-3369. 10.1182/blood-2005-03-1100, 16002429.
10. Alter G, Suscovich TJ, Kleyman M, Teigen N, Streeck H, Zaman MT, Meier A, Altfeld M. Low perforin and elevated SHIP-1 expression is associated with functional anergy of natural killer cells in chronic HIV-1 infection. AIDS 2006, 20:1549-1551. 10.1097/01.aids.0000237371.31315.48, 16847410.
11. Brunetta E, Fogli M, Varchetta S, Bozzo L, Hudspeth KL, Marcenaro E, Moretta A, Mavilio D. The decreased expression of Siglec-7 represents an early marker of dysfunctional natural killer-cell subsets associated with high levels of HIV-1 viremia. Blood 2009, 114:3822-3830. 10.1182/blood-2009-06-226332, 2773483, 19710502.
12. Mavilio D, Lombardo G, Benjamin J, Kim D, Follman D, Marcenaro E, O'Shea MA, Kinter A, Kovacs C, Moretta A, Fauci AS. Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci USA 2005, 102:2886-2891. 10.1073/pnas.0409872102, 549494, 15699323.
13. Sondergaard SR, Ullum H, Pedersen BK. Proliferative and cytotoxic capabilities of CD16 + CD56- and CD16+/-CD56+ natural killer cells. APMIS 2000, 108:831-837. 10.1111/j.1600-0463.2000.tb00006.x, 11252817.
14. Vieillard V, Fausther-Bovendo H, Samri A, Debre P. Specific phenotypic and functional features of natural killer cells from HIV-infected long-term nonprogressors and HIV controllers. J Acquir Immune Defic Syndr 2010, 53:564-573.
15. Bjorkstrom NK, Lindgren T, Stoltz M, Fauriat C, Braun M, Evander M, Michaelsson J, Malmberg KJ, Klingstrom J, Ahlm C, Ljunggren HG. Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus. J Exp Med 2011, 208:13-21. 10.1084/jem.20100762, 3023129, 21173105.
16. Gonzalez VD, Falconer K, Bjorkstrom NK, Blom KG, Weiland O, Ljunggren HG, Alaeus A, Sandberg JK. Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment. J Immunol 2009, 183:6612-6618. 10.4049/jimmunol.0901437, 19846870.
17. Nguyen S, Morel V, Le Garff-Tavernier M, Bolgert F, Leblond V, Debre P, Vieillard V. Persistence of CD16+/CD56-/2B4+ natural killer cells: a highly dysfunctional NK subset expanded in ocular myasthenia gravis. J Neuroimmunol 2006, 179:117-125. 10.1016/j.jneuroim.2006.05.028, 16904757.
18. Antonioli CM, Airo P. Dermatomyositis associated with lymphoproliferative disorder of NK cells and occult small cell lung carcinoma. Clin Rheumatol 2004, 23:239-241. 10.1007/s10067-003-0814-2, 15168153.
19. Ginaldi L, De Martinis M, Monti D, Franceschi C. Chronic antigenic load and apoptosis in immunosenescence. Trends Immunol 2005, 26:79-84. 10.1016/j.it.2004.11.005, 15668122.
20. Lutz CT, Karapetyan A, Al-Attar A, Shelton BJ, Holt KJ, Tucker JH, Presnell SR. Human NK cells proliferate and die in vivo more rapidly than T cells in healthy young and elderly adults. J Immunol 2011, 186:4590--4598. 3071442, 21402893.
21. Lopez-Verges S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, Norris PJ, Nixon DF, Lanier LL. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 2010, 116:3865-3874. 10.1182/blood-2010-04-282301, 2981540, 20733159.
22. Lopez-Verges S, Milush JM, Schwartz BS, Pando MJ, Jarjoura J, York VA, Houchins JP, Miller S, Kang SM, Norris PJ, et al. Expansion of a unique CD57NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci USA 2011, 108:14725-14732. 10.1073/pnas.1110900108, 3169160, 21825173.
23. Milush JM, Long BR, Snyder-Cappione JE, AJr C, York VA, Ndhlovu LC, Lanier LL, Michaelsson JL, Nixon DF. Functionally distinct subsets of human NK cells and monocyte/DC-like cells identified by co-expression of CD56, CD7, and CD4. Blood 2009, 114:4823-4831. 10.1182/blood-2009-04-216374, 2786291, 19805616.
24. Gonzalez VD, Falconer K, Michaelsson J, Moll M, Reichard O, Alaeus A, Sandberg JK. Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin. Clin Immunol 2008, 128:46-56. 10.1016/j.clim.2008.03.521, 18495540.
25. Novershtern N, Subramanian A, Lawton LN, Mak RH, Haining WN, McConkey ME, Habib N, Yosef N, Chang CY, Shay T, et al. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell 2011, 144:296-309. 10.1016/j.cell.2011.01.004, 3049864, 21241896.
26. De Maria A, Fogli M, Costa P, Murdaca G, Puppo F, Mavilio D, Moretta A, Moretta L. The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J Immunol 2003, 33:2410-2418. 10.1002/eji.200324141, 12938217.
27. Bigley V, Spence LE, Collin M. Connecting the dots: monocyte/DC and NK subsets in human peripheral blood. Blood 2010, 116:2859-2860. 10.1182/blood-2010-05-285676, 20947692.
28. Schakel K, Kannagi R, Kniep B, Goto Y, Mitsuoka C, Zwirner J, Soruri A, von Kietzell M, Rieber E. 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. Immunity 2002, 17:289-301. 10.1016/S1074-7613(02)00393-X, 12354382.
29. Guma M, Angulo A, Vilches C, Gomez-Lozano N, Malats N, Lopez-Botet M. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 2004, 104:3664-3671. 10.1182/blood-2004-05-2058, 15304389.
30. Guma M, Cabrera C, Erkizia I, Bofill M, Clotet B, Ruiz L, Lopez-Bote M. Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients. J Infect Dis 2006, 194:38-41. 10.1086/504719, 16741880.
31. Naeger DM, Martin JN, Sinclair E, Hunt PW, Bangsberg DR, Hecht F, Hsue P, McCune JM, Deeks SG. Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One 2010, 5:e8886. 10.1371/journal.pone.0008886, 2813282, 20126452.
32. Beziat V, Descours B, Parizot C, Debre P, Vieillard V. NK cell terminal differentiation: correlated stepwise decrease of NKG2A and acquisition of KIRs. PLoS One 2010, 5:e11966. 10.1371/journal.pone.0011966, 2917352, 20700504.
33. Campbell JJ, Qin S, Unutmaz D, Soler D, Murphy KE, Hodge MR, Wu L, Butche EC. Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immuno 2001, 166:6477-6482.
34. Frey M, Packianathan NB, Fehniger TA, Ross ME, Wang WC, Stewart CC, Caligiuri MA, Evans SS. Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets. J Immunol 1998, 161:400-408.
35. Eischen CM, Schilling JD, Lynch DH, Krammer PH, Leibson PJ. Fc receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis. J Immunol 1996, 156:2693-2699.
36. Medvedev AE, Johnsen AC, Haux J, Steinkjer B, Egeberg K, Lynch DH, Sundan A, Espevik T. Regulation of Fas and Fas-ligand expression in NK cells by cytokines and the involvement of Fas-ligand in NK/LAK cell-mediated cytotoxicity. Cytokine 1997, 9:397-404.
37. Kottilil S, Jackson JO, Reitano KN, O'Shea MA, Roby G, Lloyd M, Yang J, Hallahan CW, Rehm CA, Arthos J, et al. Innate immunity in HIV infection: enhanced susceptibility to CD95-mediated natural killer cell death and turnover induced by HIV viremia. J Acquir Immune Defic Syndr 2007, 46:151-159. 10.1097/QAI.0b013e3180dc9909, 17558334.
38. Eller MA, Eller LA, Ouma BJ, Thelian D, Gonzalez VD, Guwatudde D, McCutchan FE, Marovich MA, Michael NL, de Souza MS, et al. Elevated natural killer cell activity despite altered functional and phenotypic profile in Ugandans with HIV-1 clade A or clade D infection. J Acquir Immune Defic Syndr 2009, 51:380-389. 10.1097/QAI.0b013e3181aa256e, 19487954.
39. Bhat R, Watzl C. Serial killing of tumor cells by human natural killer cells--enhancement by therapeutic antibodies. PLoS One 2007, 2:e326. 10.1371/journal.pone.0000326, 1828617, 17389917.
40. Barker E, Martinson J, Brooks C, Landay A, Deeks S. Dysfunctional natural killer cells, in vivo, are governed by HIV viremia regardless of whether the infected individual is on antiretroviral therapy. AIDS 2007, 21(17):2363-2365. 10.1097/QAD.0b013e3282f1d658, 18090295.
41. Michaelsson J, Long BR, Loo CP, Lanier LL, Spotts G, Hecht FM, Nixon DF. Immune reconstitution of CD56(dim) NK cells in individuals with primary HIV-1 infection treated with interleukin-2. J Infect Dis 2008, 197:117-125. 10.1086/524141, 18171294.
42. Norata GD, Pirillo A, Catapano AL. Statins and oxidative stress during atherogenesis. J Cardiovasc Risk 2003, 10:181-189. 10.1097/00043798-200306000-00005, 12775950.
43. Raemer PC, Kohl K, Watzl C. Statins inhibit NK-cell cytotoxicity by interfering with LFA-1-mediated conjugate formation. Eur J Immunol 2009, 39:1456-1465. 10.1002/eji.200838863, 19424968.
44. Hecht FM, Busch MP, Rawal B, Webb M, Rosenberg E, Swanson M, Chesney M, Anderson J, Levy J, Kahn JO. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS 2002, 16:1119-1129. 10.1097/00002030-200205240-00005, 12004270.
45. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, Deeks SG. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003, 187:1534-1543. 10.1086/374786, 12721933.